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Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13.
Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP 
and calprotectin), and endoscopic findings.
Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn’s disease [CD]) were enrolled. Four hundred fifty-nine 
patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). 
All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred 
fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation 
of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy 
was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) 
lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, 
respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). 
Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with 
baseline.
Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
Key Words:  Crohn’s disease, ulcerative colitis, inflammatory bowel disease, Infliximab, Remsima, Inflectra, biosimilar, CT-P13
INTRODUCTION
The introduction of biologic therapies for inflammatory 
bowel disease (IBD) proved to be a breakthrough for patients 
with Crohn’s disease (CD) and ulcerative colitis (UC).1 Since 
infliximab (Remicade, Janssen) was approved in 1998, antitu-
mor necrosis factor alpha (anti-TNFα) monoclonal antibod-
ies (mAb) have been demonstrated to be a very potent class of 
therapeutic agents inducing mucosal healing and prolonged 
remission, with reduction of hospitalizations and surgical pro-
cedures.2 However, anti-TNFα agents are also expensive and 
have become a burden on pharmacy budgets in most countries, 
possibly restricting access for many patients.3, 4 As the patent of 
infliximab and other biologic products used for inflammatory 
diseases is expired or close to expire in the European Union 
(EU) and the United States (US), the emergence of biosimilar 
therapies is an inevitable outcome.5
CT-P13 (Celltrion, Inc., Incheon, Republic of Korea) 
has been the first mAb biosimilar of infliximab evaluated and 
approved by the European Medicines Agency (EMA) and Food 
and Drug Administration (FDA). The program to demonstrate 
its biosimilarity consisted of a phase 1 pharmacokinetic study in 
patients with ankylosing spondylitis (AS)6 and a phase 3 study 
evaluating efficacy in patients with rheumatoid arthritis (RA).7 
Both were randomized, double-blinded, multinational trials 
and provided data up to 30 weeks of treatment.6, 7 Subsequently, 
data up to 54 weeks8–10 with a following open-label 48-week 
extension, in which patients initially receiving reference inflix-
imab were switched to CT-P13, have been published.11, 12 These 
studies have demonstrated pharmacokinetic equivalence and 
clinical efficacy in both AS and RA6, 7 up to 102 weeks and in 
patients switched from infliximab to CT-P1311, 12. The develop-
ment of antidrug antibodies (ADA) was similar in CT-P13 and 
infliximab in both trials.7, 12
Based on extensive in vitro product characterization, 
comparability exercise,13 and these clinical data, CT-P13 
became the first mAb in 2013 approved by the EMA14 not only 
in RA and AS but also in adult and pediatric CD and UC, 
psoriatic arthritis, and psoriasis. Similarly, it has been licensed 
for all these indications in South Korea,15 Japan,16 the United 
States,17 and Canada.18
The introduction of biosimilars has certainly reduced 
the financial burden and generated competition in the phar-
maceutical market, allowing more patients to access the treat-
ment.19 However, there was an initial lack of experience and 
confidence in using biosimilar infliximab in IBD,20 both because 
of the lack of clinical studies in IBD and potential different 
downstream effects in the mechanism of action21 and different 
immunogenicity22 of infliximab in IBD compared with rheuma-
tologic diseases. Of note, infliximab in RA is thought to act 
predominantly through the neutralization of soluble and trans-
membrane TNFa, whereas in CD, signalling through mem-
brane-associated forms of TNFa and Fcg receptor seems to 
play a more important role.23, 24
Most information about the efficacy and safety of 
CT-P13 in IBD patients naïve to anti-TNFα or after switching 
from infliximab were confined to studies with small sample size 
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and short follow-up, as recently reviewed by Komaki Y et al in 
2017.25
A single randomized controlled noninferiority, dou-
ble-blinded, phase 4 trial with 52 weeks of follow-up has been 
recently published (NCT02148640).26 Adult patients on stable 
treatment with infliximab originator with different immune-me-
diated diseases treated in a hospital setting for at least 6 months 
were eligible for participation. Four hundred eighty-two 
patients were enrolled and randomized (241 to infliximab orig-
inator, 241 to CT-P13 group), including 155 and 93 patients 
with CD and UC, respectively. After switching to biosimilar, 
the frequency of serious adverse events (10% vs 9%) and disease 
worsening (26% vs 30%) was similar in patients using infliximab 
or CT-P13.
Since February 2015, the patent for infliximab is expired 
in Italy, and two CT-P13 formulations became available on 
market, REMSIMA (Celltrion Healthcare Hungary Kft. 
1023 Budapest) and INFLECTRA (Hospira, UK Limited, 
Maidenhead UK). We planned a prospective, nationwide, 
observational study to evaluate the effectiveness, safety, and 
immunogenicity of CT-P13 in patients with IBD, in induction 
and maintenance of remission, either in patients naïve to anti-
TNFα, previously exposed to anti-TNFα, or switched from 
infliximab. The preliminary data of 547 patients with a mean 
follow-up of 4.3 months have been published elsewhere.27
We report here an expansion of the original cohort 
(n = 810), with a mean follow-up of 1 year and—more impor-
tantly—including data on modification of endoscopic activity 
and inflammatory biomarkers.
METHODS
Study Population and Data Collection
Consecutive IBD patients treated with CT-P13 were 
enrolled in 30 academic (n = 12), and tertiary (n = 18) refer-
ral centers in Italy from April 2015 to August 2017. Eligible 
patients were previously diagnosed either as UC or CD based 
on clinical, radiological, endoscopic, and histological crite-
ria.28–30 Clinical data were anonymized and organized in a struc-
tured database during the entire follow-up. The study protocol 
was approved by each participating center and registered as 
EUDRACT 2015-005254-35.
For each patient, the following clinical features were col-
lected: gender, age at diagnosis, type of disease, age at start of 
therapy with CT-P13, commercial name and batch of CT-P13, 
use of combo therapy, indication for CT-P13 therapy, pre-
vious therapy with anti-TNFα (name of drug, duration, and 
results), duration of follow-up with CT-P13, number of infu-
sions of CT-P13, evaluation of efficacy with reason for with-
drawal, other immune-mediated associated diseases, number 
and details of serious adverse events, date of last follow-up, 
and any occurrence of surgery along the follow-up. The clinical 
and endoscopic evaluation was performed in UC by using the 
Mayo score, while the Harvey-Bradshaw index (HBI), Simple 
Endoscopic Score (SES-CD), and Rutgeerts score were used 
for CD. In addition, rate of primary failure, loss of response, 
and need for dose escalation were also recorded (see further for 
definitions). According to site routine clinical practice, blood 
samples were taken at different time points for evaluation of 
C reactive protein (CRP), fecal calprotectin (FC), detection of 
drug trough levels (TL), and antidrug antibodies (ADA).
Outcome Measures
The primary endpoint was the evaluation of safety in 
terms of rate of serious adverse events (SAEs) along the fol-
low-up. Secondary endpoints were a) the effectiveness, evalu-
ated both in terms of clinical remission/response and treatment 
persistency; b) the change of HBI, Mayo Score, SES-CD, 
Rutgeert’s score, CRP, and FC; c) the immunogenicity evaluated 
as the occurrence of infusion reactions and loss of response; 
and d) predictive factors of safety and efficacy.
Serious adverse events (SAEs) were defined as the occur-
rence of death, a life-threatening adverse event, impatient 
hospitalization, prolongation of existing hospitalization, a per-
sistent or significant incapacity or substantial disruption of the 
ability to conduct normal life functions, and any condition that 
on appropriate medical judgement might jeopardize the patient 
and might require medical or surgical intervention, including 
withdrawal of the ingoing therapy with CT-P13.
Clinical remission for UC was considered as a partial 
Mayo score (pMS) <2 with no partial score >1 and no rectal 
bleeding, whereas response was a 30% and 3 points reduction 
of pMS.31 Clinical remission for CD was considered a Harvey-
Bradshaw Index (HBI) ≤4, whereas response was taken as a 
3-point reduction of HBI.32 Endoscopic remission was defined 
as endoscopic Mayo score of 0, SES-CD <4, and Rutgeerts 
score ≤ir2, respectively.
Primary failure of CT-P13 was defined as no or minor 
clinical response at 8 weeks after the induction regimen or dete-
rioration of clinical condition leading to surgery, early therapy 
change, or withdrawal.33 Loss of response was defined as a 
clinical situation arising in patient with an initial response to 
the CT-P13, followed by a diminished or less durable response 
over time leading to drug discontinuation or dose escalation, 
according to investigator’s evaluation.34, 35 Dose escalation was 
performed as either increasing dosage (10 mg/Kg) or reducing 
the infusion intervals (every 4–6 weeks), according to investiga-
tor’s preference.
Statistical Analysis
Descriptive statistics of the baseline data are presented 
as means ± standard deviation (SD), medians and interquartile 
ranges (IQR), or as percentages, when appropriate. Most vari-
ables were non-normally distributed; thus, nonparametric tests 
(the χ
2
 test and the Kruskal-Wallis [equality-of-populations] 
rank test) were used.
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Primary failure to CT-P13 was assessed among patients 
who had completed a minimum treatment and follow-up time 
of 8 weeks. Then, loss-of-response was studied among respond-
ers at week 8 using time-to-event methods for censored obser-
vations (i.e., patients withdrawn from the study due to AEs and 
patients who had not lost response on the final data collection 
date were considered “censored”). On the other hand, patients 
for whom treatment dose was optimized were considered to 
have lost response. Time to event was defined as the time from 
week 8 until the date of event or censoring. Kaplan-Meier esti-
mates were used to draw cumulative incidence curves, compared 
by the log-rank test and Hazard Ratios (HR) derived from Cox 
proportional hazards analysis. In an alternative approach, 
we analyzed treatment persistency, taking into account those 
patients for whom treatment dose was optimized while remain-
ing on CT-P13 treatment.
P values less than 0.05 were considered statistically sig-
nificant. All statistical tests are 2-sided. Stata software was used 
for all statistical analyses (Stata Corp., College Station, TX, 
USA).
RESULTS
The main clinical characteristics of the study cohort are 
summarized in Table 1.
The study population included 810 patients (452 CD, 358 
UC): 459 were naïve to anti-TNFα (group A); 196 were pre-ex-
posed to 1 or more anti-TNFα agents (group B) (36 infliximab, 
124 adalimumab, 27 golimumab, and 9 had two different anti-
TNFα). The anti-TNFα agents were stopped in these patients 
for any reasons except intolerance 4 to 24 months before start-
ing CT-P13. The remaining 155 patients were switched from 
infliximab to CT-P13 after a mean of 17 ± 13 infusions (range 
2–72) (group C). The 3 groups differed regarding type of dis-
ease (CD or UC), age at diagnosis, frequency of combo therapy 
(usually with thiopurines), use of steroids at baseline, and aver-
age time of follow-up, but not for disease duration, gender, and 
smoking status.
Of note, 51 pediatric patients were also included in the 
cohort (31 CD); 27 of them naïve to anti-TNFα, and the 
remaining switched from infliximab.
Safety
Two hundred ninety patients received Inflectra and the 
remaining 520 Remsima, for a cumulative number of 6,501 
infusions and a mean follow-up of 344.7 ± 215.6 days (median 
327, IQR: 161–530 days) and 764 patient-years. Main data are 
given in Tables 2 and 3.
Any serious adverse events
Serious adverse events (including infusion reactions) 
occurred in 79 of 459 patients (17%) in group A; 57 of 196 
(29%) in group B; and 18 of 155 (11.6%) in group C.  The 
detailed list of SAEs is depicted in Table 2. More specifically, 
most common infections were pneumonitis (4 cases) and herpes 
zoster (3 cases). The corresponding rates (with person-years in 
the denominator) were 74, 48.5, and 18.5 per 100 person-years 
(p-y) for groups A, B, and C, respectively.
When the incidence rates were calculated as relative risk 
(Table 3), SAEs in patients who had been previously exposed to 
anti-TNFα were twice as frequent as in naïve patients and 2.5 
times as frequent as in patients who switched (both comparison 
were statistically significant).
TABLE 1: Characteristics of Naïve Patients (group A, n = 459); Patients Previously Exposed to Anti-TNFs (group B, 
n = 196); and Patients Who Switched from Infliximab (group C, n = 155)
Total Cohort group A group B group C P
Gender
(males, %)
450/360 (55%) 246/213 (53%) 106/90 (54%) 98/57 (63%) 0.20
Diagnosis (CD/UC) 452/358 238/221 127/69 87/68 0.025
Age at diagnosis (yrs) 31.8 ± 13.7
29 (22–41)
32.6 ± 13.6
30 (22–41)
31.3 ± 14
28 (21–44)
29.3 ± 13.6
27 (18–38)
0.069
Duration of  disease (yrs) 8.1 ± 7.9
5.5 (2–12)
7.1 ± 8
4 (1–11)
9.7 ± 7.8
7 (3–15)
8.8 ± 7.4
7 (3–13)
0.1
Smoking status (Yes/No/Ex) 133/573/104 81/319/59 34/132/30 18/122/15 0.35
Active smokers 133/677 (16.4%) 81/378 (17.6%) 34/162 (17.3%) 18/137 (11.6%) 0.35
Combo therapy (y/n) 175/635 (21.6%) 76/383 (16.5%) 51/145 (26%) 48/107 (31%) 0.0006
Steroids (y/n) 279/531 (34.4%) 190/269 (41.4%) 68/128 (34.7%) 21/134 (13.5%) <0.00001
Follow-up (days) 344.7 ± 215.6
327 (161–530)
342.4 ± 206.4
335 (165–511)
312.2 ± 216.3
285 (126–497)
392.8 ± 232
356 (184–629)
0.009
Data are presented as means ± SD; medians and interquartile ranges in bracket, or percentages when appropriate. The 2 test and the Kruskal-Wallis (equality-of-populations) 
rank test were used for the statistical evaluations.
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Any serious adverse events (excluding infusion 
reactions)
Aside from infusion reactions, other serious adverse 
events occurred in 45 of 459 patients (9.8%) in group A; 31 of 
196 (15.8%) in group B; and 18 of 155 (11.6%) in group C. The 
corresponding rates were 42, 26.4, and 19 per 100 p-y for groups 
A, B, and C, respectively. The relative risk was significantly 
more frequent in group B compared with group A (P = 0.03) 
and C (P = 0.0019). The most frequent events were skin reac-
tions. No death, neoplasia, or unexpected SAEs were reported.
Infusion reactions
Infusion reactions occurred in 34 of 459 patients (7.4%) 
in group A, 26 of 196 (13.2%) in group B, and 11 of 155 (7.1%) 
in group C. The corresponding rates were 31.8, 22.5, and 11.8 
per 100 p-y for groups A, B, and C, respectively. Infusion reac-
tions in patients previously exposed to anti-TNFα were twice 
as frequent as for naïve patients and twice as frequent as in 
patients who switched. Only the first comparison was statisti-
cally significant (P = 0.017). By evaluating patients of group B, 
it was discovered that 45 were previously exposed to infliximab 
and 151 were not. Among the 45 previously exposed to inflix-
imab, 11 infusion reactions (24.4%) were reported. Among the 
151 previously exposed to other anti-TNFα, 15 infusion reac-
tions (9.9%) were reported. This gives a relative risk of =2.24 
(1.21–4.97), P = 0.012.
Serious adverse events leading to discontinuation 
(excluding infusion reactions)
Serious adverse events leading to discontinuation 
occurred in 30 of 459 patients (6.5%) in group A; 14 of 196 
(7.1%) in group B; and 6 of 195 (3.9%) in group C. By consider-
ing these SAEs, no significant difference was found among the 
3 groups. More specifically, they were skin lesions (16), serious 
TABLE 2: Type of SAEs in the Whole Cohort and in the Three Different Subgroups
Total Cohort
(n = 810)
Naïve to anti-TNFα  
(n = 459) A
Pre-exposed to anti-TNFα 
(n = 196) B
Switch from
infliximab (n = 155) C
Total SAEs, n (%) 154 (19%) 79 (17%) 57 (29%) 18 (11.6%)
Infusion reactions, n (%) 71 (8.7%) 34 (7.4%) 26 (13.2%) 11 (7.1%)
Skin reactions, n (%) 34 (4.2%) 20 (4.3%) 11 (5.6%) 3 (1.9%)
Infections, n (%) 14 (1.7%) 7 (1.5%) 6 (3.1%) 1 (0.6%)
Others, n (%) 16 (2%) 11 (2.4%) 5 (2.5%) 0
Arthralgia, n (%) 8 (1%) 5 (1.1%) 3 (1.5%) 0
Neurological, n (%) 3 (0.4%) 1 (0.2%) 1 (0.5%) 1 (0.6%)
Immunological, n (%) 8 (1%) 1 (0.2%) 5 (2.5%) 2 (1.3%)
Neoplasia, n (%) 0 — — —
Death, n (%) 0 — — —
Drug withdrawal, n (%) 103 (12.7%) 58 (12.6%) 35 (17.8%) 10 (6.4%)
Stop for infusion reactions, n (%) 53 (6.5%) 28 (6.1%) 21 (10.7%) 4 (2.6%)
Stop for SAEs, n (%) 50 (6.2%) 30 (6.5%) 14 (7.1%) 6 (3.9%)
TABLE 3: Evaluation of the Relative Risk of the SAEs and Infusion Reactions in the Three Subgroups of Patients. 
Values Given With 95% Confidence Interval and P.
All SAEs Infusion reactions Other SAEs
Stop for SAEs
(no infusion) Stop for infusion reactions
Group A vs
Group B
0.59
(0.43–079)
0.0005
0.55
(0.34–0.90)
0.017
0.62
(0.4–0.95)
0.03
0.91
(0.49–1.68)
0.7
0.56
(0.33–0.97)
0.04
Group A vs
Group C
1.48
(0.91–2.39)
0.10
1.04
(0.54–2)
0.89
2.17
(0.99–4.7)
0.05
1.68
(0.71–3.97)
0.2
2,36
(0.84–6.63)
0.10
Group B vs
Group C
2.5
(1.5–4.1)
0.0002
1.86
(095-3.66)
0.06
3.5
(1.58–7.73)
0.0019
1.84
(0.72–4.69)
0.19
4.15
(1.45–11.8)
0.0078
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infections (11), immunologic problem (7), severe arthralgia (6), 
surgery for perianal fistula (4), transient ischemic attack (2), 
headache (1), alteration of liver functions tests (2), and lack of 
adequate venous access (1).
Infusion reactions leading to discontinuation
Infusion reactions leading to discontinuation occurred in 
28 of 459 patients (6.1%) in group A; 21 of 196 patients (10.7%) 
in group B; and 4 of 155 patients (2.6%) in group C. The rela-
tive risks ratios were significantly higher in patients previously 
exposed to anti-TNFα but did not differ among groups A and 
C. Infusion reactions were twice as frequent as in naïve patients 
and four times as frequent as in patients who switched. Both 
comparisons were significant (P  =  0.04; P  =  0.0078, respec-
tively). Within the group, the discontinuation due to infusion 
reaction was significantly more frequent in patients previously 
exposed to infliximab compared with other anti-TNFα (20% vs 
8%; relative risk 2.5; 95% CI, 1.13–5.58; P = 0.023).
Of note, at the end of follow-up (August 2017), in 78 
patients a colectomy (34 UC) or intestinal resection (44 CD) 
was performed or planned. Forty-nine patients were naïve to 
anti-TNF, 18 were pre-exposed, and the remaining 11 patients 
(10 CD) were switched after a mean of 36 months of infliximab 
therapy (range 8–66  months) and 13.8  months of biosimilar 
(range 5–24 months). The rate of surgery was 10.6%, 9.3%, and 
7.1% with no significant difference among groups A, B and C, 
respectively.
Effectiveness
Overall, 754 patients had completed the minimum treat-
ment and follow-up time of 8 weeks or had failed earlier. There 
were 433 in group A, 170 in group B, and the remaining 151 
in group C.  Among them, 48 patients had a primary failure 
(6.4%, 95% CI, 5.7–11.0); more specifically, the failure rate was 
7.4% in group A (95% CI: 5.2%–10.2%), 7.6% in group B (95% 
CI: 4.5%–12.6%), and 2% in group C (95% CI: 0.7%–5.7%) 
(P = 0.047).
Next, we explored the loss of response among week 8 
responders (n  =  722) using time-to-event methods. One hun-
dred eighty-eight patients (25.6%) lost response during the 
follow-up (from week 8 onwards: total time at risk was approx-
imately 609 patient-years or 315 days per patient on average).
In Figure 1, the Kaplan-Meier estimates for the probabil-
ity to respond are shown up to the end of follow-up. A signifi-
cant difference between the 3 groups was found (log rank test, 
P = 0.01) (Fig. 1). More specifically, patients of group C did sig-
nificantly better than those of groups A and B (P = 0.006 and 
P = 0.004, respectively). However, this finding should be tem-
pered by considering that most patients in group C were already 
responders at the time of switching and more frequently under 
combo therapy compared with naïve (31% vs 21%; P   0.001). 
The Kaplan-Meier estimates (with 95% CIs) for probability of 
response at predetermined time-points are depicted in Table 4.
In an alternative approach, we evaluated treatment per-
sistency among responders at week 8 (n = 722). In 78 patients 
(10.5%), treatment was withdrawn during follow-up, and dose 
intensified in 203 (27.5%) more patients. Kaplan-Meier esti-
mates for probability of treatment persistency are depicted in 
Fig. 2. In this evaluation, difference among subgroups was not 
statistically significant (log rank test, P = 0.25). The Kaplan-
Meier estimates (with 95% CIs) for probability of treatment per-
sistency at predetermined time-points are depicted in Table 4.
Clinical scores
The clinical scores at baseline, 6 months, and 12 months 
are summarized on Table  5. For UC, 358 patients were eval-
uated at baseline, 264 after 6 months, and 138 at 12 months. 
Of note, 70 and 8 patients were still available up to 18 and 
FIGURE 1. Kaplan-Meier estimation for probability of response in 
groups A (black), B (blue), and C (red). Total Log-rank test: P = 0.01; A vs 
B P = 0.46, B vs C P = 0.004; A vs C P = 0.006
FIGURE 2. Kaplan-Meier estimation for probability of treatment per-
sistency in groups A (black), B (blue), and C (red). Total Log-rank Test: 
P = 0.25; A vs B P = 0.70; A vs C P = 0.28; A vs C P = 0.09
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24 months, respectively. For CD, 452 patients were evaluated at 
baseline, 364 at 6 months, and 222 at 12 months. In addition, 
124 and 18 patients reached a follow-up of 18 and 24 months, 
respectively.
Both Mayo score and HBI in the full cohort decreased 
significantly at month 6 (P  <  0.0001) and remained stable at 
month 12. This reduction was significant not only in groups 
A and B (P < 0.0001) but also in group C (P = 0.01, P < 0.001), 
despite lower baseline values being most of the patients already 
in remission at the start of biosimilar infusion.
Endoscopic scores
An endoscopic evaluation was available at baseline and 
after 12 months in 333 of 358 (93%) and 131 of 138 (95%) of 
UC and 343 of 452 (76%) and 135 of 222 (61%) of CD patients, 
respectively. More specifically, in 43 CD patients, the biosimilar 
therapy was undertaken for postsurgical recurrence and endo-
scopic activity evaluated with the Rutgeerts score. The Mayo 
score and SES-CD were both significantly improved (P < 0.0001) 
at the evaluation at 12  months. After stratifying patients in 
groups, besides the significant improvement for groups A and B 
(P = 0.002, P < 0.0001), a further improvement in group C was 
calculated (Mayo: P = 0.01; SES-CD: P = 0.06). The Rutgeerts 
score was significantly improved in the whole cohort (P = 0.01), 
with a trend toward improvement in all subgroups.
Inflammatory biomarkers
C reactive protein evaluation was available in 805, 620, 
and 355 of patients at baseline, 6 moths, and 12 months, respec-
tively; fecal calprotectin was available only in approximatively 
25% of cases. In the overall cohort, CRP and calprotectin were 
significantly reduced from the baseline to 6 and 12  months 
(P < 0.01 to <0.0001).
After stratifying by groups in UC patients, a significant 
reduction of CRP was found in groups A and B, while there 
was no significant change compared with baseline in group 
C. In Crohn’s disease, a significant reduction for CRP in groups 
A and B was found, but not in group C.
The calprotectin was significantly reduced in UC and CD 
patients in groups A  and B and only numerically reduced in 
group C.
Deep remission
At the end of follow-up, a deep remission including clini-
cal remission, mucosa healing and normalization of inflamma-
tory biomarkers was achieved in 48 of 117 (41%) and 35 of 141 
(25%) of CD and UC patients in whom all information were 
available, respectively.
Steroids free remission
At the beginning of biosimilar therapy, 167 of 358 UC 
patients (46.6%) and 112 of 452 CD patients (24.8%) were on 
steroid therapy, mainly in groups A (n = 190) and B (n = 68). 
At the last follow-up, 61 (17%) UC and 45 (10%) CD patients 
were still on steroids. However, only 5 of 231 (2.2%) CD and 6 
of 150 (4%) UC patients in clinical remission, respectively, were 
still on steroid therapy.
Multivariate analysis
The Cox proportional hazards analyses identified some 
prognostic factor for loss of response and SAEs (Supplementary 
Tables 1 and 2). More specifically, patients of groups A and B 
and UC patients had a significantly greater hazard ratio (HR) 
to lose response (P  =  0.033; P  =  0.024; P  =  0.028, respec-
tively), while the opposite was true for patients with no ste-
roids at last follow-up (<0.0001). By evaluating risk factors 
for SAEs, patients of subgroup B had a significantly higher 
HR (P  =  0.003), and a similar trend was also seen in group 
A  (P  =  0.057); conversely, the HR was significantly lower in 
male compared with female patients (P = 0.001) and patients 
off  steroids at last follow-up (P = 0.010).
Cost savings
Estimated cost saving was over 3.8 million Euros per 
year of treatment in our cohort, by considering approximately 
TABLE  4: Kaplan-Meier Estimates (With 95% CIs) for Probability of Response and Persistency at Predetermined 
Time-points After the Initial 8 Weeks of Therapy
RESPONSE Overall Group A Group B Group C
6 months 83% (80–86) 83% (80–87) 75% (69–82) 90% (84–95)
12 months 72% (68–76) 71% (66–76) 64% (56–73) 82% (75–90)
18 months 64% (60–69) 61% (55–68) 60% (50–72) 77% (68–86)
24 months 58% (55–66) 52% (47–63) 58% (50–72) 75% (67–84)
6 months 93% (91–95) 93% (91–98) 89% (84–94) 96% (94–99)
12 months 90% (87–92) 89% (85–91) 87% (81–92) 95% (90–99)
18 months 86% (82–89) 84% (79–88) 84% (78–91) 91% (86–97)
24 months 84% (80–87) 81% (75–85) 82% (76–89) 90% (85–91)
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TABLE  5: Clinical and Endoscopic Scores and Biomarkers in the Whole Cohort and Different Subgroups at the 
Beginning of the Biosimilar Treatment, at 6 Months, 12 Months, and Final Follow-Up. P Values Obtained by Student 
T test. Baseline Values Compared With 6 (a) and 12 (b) Months
Parameters Baseline 6 months 12 months P
UC Total (n = 358) (n = 264) (n = 138)
Mayo Score 6 ± 3 2.2 ± 2.3 1.6 ± 2.1 <0.0001a,b
Mayo Endo 2.38 ± 0.85 — 1.2 ± 1.2 <0.0001b
CRP (mg/L) 14.2 ± 25.4 4.9 ± 12.3 4.5 ± 8.8 <0.0001a,b
Calpro (mcg/g) 686.2 ± 700.5 395 ± 611.1 164.3 ± 391.5 0.01a, <0.001b
UC group A (n = 221) (n = 147) (n = 95) —
Mayo Score 6.6 ± 2.4 4.1 ± 2.3 1.8 ± 2.3 <0.0001 a,b
Mayo Endo 2.5 ± 0.6 — 1.4 ± 1.3 <0.0001 b
CRP (mcg/g) 15.5 ± 26.9 5.6 ± 14.9 3.9 ± 6.7 <0.0001 a,b
Calpro (mcg/g) 745 ± 745 338 ± 573 298 ± 513 0.01a, 0.007b
UC group B (n = 69) (n = 62) (n = 15) —
Mayo Score 6.9 ± 2.3 2.1 ± 2.4 1.5 ± 1.7 <0.0001a,b
Mayo Endo 2.5 ± 0.5 — 0.8 ± 0.7 0.002b
CRP (mcg/g) 12.8 ± 18.2 4.3 ± 4.4 5.9 ± 8.1 0.002a, 0.09b
Calpro (mcg/g) 719 ± 658 220 ± 131 50 ± 53 0.009a,b
UC group C (n = 68) (n = 55) (n = 28) —
Mayo Score 3 ± 3.5  1.3 ± 1.9 1.1 ± 1.7 <0.001a,b
Mayo Endo 1.4 ± 1.2 — 0.9 ± 0.7 0.01b
CRP (mcg/g) 4 ± 7.8 2.78 ± 10.5 7.4 ± 17.3 NS
Calpro (mcg/g) 412.6 ± 461 592 ± 922 13.9 ± 9.5 NS
CD Total (n = 452) (n = 364) (n = 222) —
Harvey-Bradshaw 6.9 ± 4.4 3.1 ± 2.9 2.6 ± 2.7 <0.0001a,b
SES-CD 9.4 ± 6.4 — 3.9 ± 4.5 <0.0001a,b
Rutgeerts score 3.3 ± 1.1 — 2.4 ± 1.3 0.01b,
CRP (mcg/g) 11.2 ± 18.5 5.7 ± 11 5.1 ± 7.5 0.04a, <0.01b
Calpro (mcg/g) 477.9 ± 563.9 279.6 ± 409.5 173.7 ± 343.9 0.006a, 0.001b
CD group A (n = 238) (n = 190) (n = 116) —
Harvey-Bradshaw 7.5 ± 4 2.8 ± 2.9 2.6 ± 2.7 <0.0001a,b
SES-CD 10.8 ± 5.5 — 4.6 ± 5.1 <0.0001b
Rutgeerts score 3.8 ± 0.5 — 2.9 ± 1.2 0.07b
CRP (mcg/g) 13.4 ± 20.7 6.6 ± 10.8 5.2 ± 7.8 0.0001a,b
Calpro (mcg/g) 548 ± 647 275 ± 455 201 ± 402 0.01a, 0.007b
CD group B (n = 127) (n = 96) (n = 58) —
Harvey-Bradshaw 8.6 ± 4.3 3.9 ± 3.5 3.7 ± 3.3 <0.0001a,b
SES-CD 11.1 ± 6.9 — 4.8 ± 4 <0.0001b
Rutgeerts score 3.2 ± 1.2 — 2.7 ± 1.3 0.3
CRP (mcg/g) 11.4 ± 18.3 6 ± 13.3 5.2 ± 8 0.02a, 0.004b
Calpro (mcg/g) 444 ± 389 131 ± 93 123 ± 89 0.001a, 0.009b
CD group C (n = 87) (n = 78) (n = 48) —
Harvey-Bradshaw 3 ± 3.2 2.1 ± 2.4 1.8 ± 2.3 0.01a,b
SES-CD 3.7 ± 4.5 — 1.5 ± 2 0.06b
Rutgeerts score 2.8 ± 1.2 — 1 ± 0.7 0.01b
CRP (mcg/g) 2.9 ± 2.8 2.2 ± 2.7 3.2 ± 3.1 NS
Calpro (mcg/g) 289.2 ± 356 165.3 ± 330 110 ± 188 NS
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350 mg of CT-P13 for each infusion, with a mean 35% price 
reduction compared with Remicade’s cost.
DISCUSSION
 In this study, we prospectively followed a large cohort 
of patients using CT-P13, the first mAb approved in IBD, in 
real-life condition. The main findings are that a) the rate (19%) 
and characteristics of SAEs are in line with previous experience 
with infliximab; b) the occurrence of infusion reactions and 
drug withdrawal for SAEs was 8.7% and 12.7%, respectively; 
c) drug withdrawal due to infusion reactions was significantly 
more frequent in patients pre-exposed to anti-TNFα, especially 
infliximab; d) the whole effectiveness in terms of induction 
or maintainance of remission/response was high with an esti-
mated effectiveness at 12  months of about 71% in naïve and 
82% after the switch; e) the rate of primary failure (6.4%) and 
loss of response (25.6%) is in line with previous experience with 
infliximab; and f) after the switch, patients had less or com-
parable incidence of SAEs and significantly lower rate of loss 
of response as compared with patients naïve or pre-exposed to 
anti-TNFα.
The availability of the mAB biosimilar on the market 
has been a major breakthrough because of the pharmaco-eco-
nomic implications. In the United States, because of the raising 
prescription, biologics as a whole account for 28% of all drug 
spending, and it is expected that biologic sales will reach $180 
billion USD during 2017.36 Approximatively half  of these sales 
will likely be attributed to 11 biologics that will lose exclusivity 
within the next 5 years.36 Biosimilars are less costly primarily 
because they do not have to undergo the intensive clinical devel-
opment process of approval and have a reduced cost of market-
ing. IMS Health in 2016 estimated that the use of biosimilars 
would save over $56 billion USD and potentially up to $112 bil-
lion for the health care system in Europe and the United States, 
respectively, over the following 5 years.37 The anti-TNFα bio-
similar has already a 72% share in Europe with an increase in 
volume of prescription (infliximab + biosimilar) of about 20%. 
The use of biosimilars by reducing the cost of IBD treatment 
can potentially improve access to medication. This has already 
proven to be the case in several European countries.38
 An important issue, however, is the extrapolation to the 
same indications of the originator in the absence of clinical 
data and the dilemma that clinicians face utilizing new biotech 
agents with scarce clinical information in their own disease of 
interest. This is the case now for CT-P13 and Flixabi in Italy for 
IBD, but it will be the same in the near future for other inflix-
imab and adalimumab biosimilars.39, 40
 Although introduced in 2013 in Korea, data on safety 
and efficacy of CT-P13 in IBD are still scanty. A recent system-
atic review and meta-analysis reported data of only 829 patients 
from 11 observation series. Adverse events in naïve patients 
were 0.08 (95% CI, 0.02–0.26) and 0.08 (95% CI, 0.03–0.17) in 
CD and UC, respectively, with as slight numerical increase after 
switching (CD = 0.10 [95% CI, 0.02–0.31]; UC 0.22 [95% CI, 
0.04–0.63]). The pooled rate of clinical response at 24–30 weeks 
were 0.77 (95% CI 0.62–0.86) and 0.77 (95% CI 0.67–0.85) in 
CD and UC, respectively. After switching the sustained clini-
cal response at 48–63 weeks were 0.75 (95% CI, 0.44–0.92) and 
0.83 (95% CI, 0.19–0.99). Of note, the largest cohort had 210 
patients followed for 54 weeks.41 After this review, a few other 
large series have been published, including our own.42–51
 The occurrence of SAEs in our study (19%) is in line with 
previous experience with infliximab and CT-P13, and no unex-
pected safety signals have been reported in the evaluated time-
frame, although the median duration of treatment for a single 
patient was still 11  months. Of note, skin reactions were the 
most frequent SAEs (34 of 810, 4.2%), excluding infusion reac-
tions, and lead to drug withdrawal in 16 patients. More impor-
tantly, infusion reactions were significantly more frequent in 
patients pre-exposed (13.2%) with a double relative risk com-
pared with naïve patients (P = 0.017) or those who switched 
from infliximab (P = 0.06). In group B, infusion reactions were 
more than twice as frequent in patients previously exposed to 
infliximab compared with patients exposed to other anti-TNFα 
agents. Similarly, infusion reactions leading to discontinuation 
were twice as frequent as in naïve patients, and 4 times as fre-
quent as in patients who switched, being significantly more fre-
quent in patients previously exposed to infliximab (RR = 2.5, 
P  =  0.023), thus suggesting specific caution in these patients 
(Tables 2 and 3).
 The clinical effectiveness was evaluated during a median 
of 11  months, although the follow-up was significantly lon-
ger in patients who switched from infliximab (11.9  months). 
Given these differences, the estimated efficacy was calculated 
using time-to-event methods for censored observations up to 
24 months from the beginning of therapy. Seven hundred fif-
ty-four patients had at least 8 weeks of follow-up or had failed 
earlier; 38 were primary failures (6.4%). In the remaining sub-
ject responders at 8 weeks, 72% and 58% did not lose efficacy 
at 12 and 24 months, respectively (Table 5). When considering 
patients still under treatment after dose optimization, they were 
90% and 84% at 12 and 24 months, respectively (Table 4). Next, 
we evaluated possible differences among groups; no signifi-
cant difference in term of loss of response and persistency was 
found among patients naïve to or pre-exposed to anti-TNFα 
therapy (Figs. 1 and 2).
The great strength of this study is that besides the clini-
cal evaluation, we have information at baseline, 6 months, and 
12 months regarding inflammatory biomarkers and endoscopic 
activity. In Table 4, these data are depicted as total cohort of 
CD and UC and split in subgroups. In the overall cohort and 
all subgroups, there was a significant improvement both in CD 
and UC patients in the clinical score at 6 and 12 months (HBI 
and Mayo, P < 0.0001) and the endoscopic score at 12 months 
(Mayo, SES-CD, P < 0.0001) (Rutgeerts, P = 0.01). In addition, 
CRP was significantly improved at 6 and 12  months in both 
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UC patients (P < 0.0001) and CD patients (6 months P = 0.04, 
12 months P < 0.01). Similarly, calprotectin was significantly 
improved at 6 and 12 months in UC (P = 0.01, P < 0.0001) and 
CD patients (P = 0.006, P = 0.001), respectively.
 It is still debated whether switching between biosimilar 
and originator biologic is still appropriate in a patient who is 
doing well not because of medical reason but to save money. 
The NOR-SWITCH study is the only controlled trial available 
to look at this issue, but several methodological issues have been 
raised.52 The study did not include information such as mucosal 
healing, had a duration of 52 weeks, and looked at different end-
points with different disease states with an arbitrary cutoff of a 
clinical insignificance difference of 15%. Because of the nonin-
feriority design, a very large sample size would have been needed 
to discern meaningful differences, while only fewer than 250 
IBD patients were enrolled, and only a single switch from the 
originator to the biosimilar was evaluated. Another study, spon-
sored by Celltrion, has been designed to assess noninferiority in 
efficacy and to assess overall safety of CT-P13 compared with 
infliximab in patients with active Crohn’s disease up to week 54 
[ClinicalTrials.gov Identifier: NCT02096861]. This study will 
also provide information about switching from infliximab to 
CT-P13 and from CT-P13 back to infliximab; the enrollment is 
closed with 220 patients included, but no data are available yet.
 In our study, which reports thus far the largest number of 
IBD patients (n = 155) switched from infliximab to biosimilar, 
including the NOR-SWITCH trial, data are reassuring. Not only 
was the rate of SAEs numerical lower than naïve and pre-ex-
posed patients despite a significantly longer follow-up but loss 
of response was also significantly lower (P = 0.004) with a trend 
toward and higher persistency of treatment (P = 0.09). This is 
probably explained also by selection bias, since patients were 
already responders and “tolerant” to infliximab therapy, with a 
significant higher use of combo therapy compared with naive. 
Interestingly, we demonstrated in this subgroup of patients that 
at 12  months, there was a significant further improvement of 
total Mayo score and endoscopic Mayo score in UC patients and 
HBI, SED CD and Rutgeert’s scores in CD patients, respectively, 
despite the fact that patients were mostly under remission at the 
time of switching. C reactive protein and calprotectin, although 
declining, did not reach a statistical difference. Similar data have 
been reported in other noncontrolled cohorts.42, 44, 46, 49, 51
 Using the multivariate analysis, some predictive factors 
of loss of efficacy and SAEs were identified. Hazard ratios (HR) 
for loss of response were significantly increased in UC vs CD in 
patients of subgroups A and B vs C, while significantly decreased 
in patients without steroids at last follow-up. The HR for SAEs 
was significantly higher in group B vs C and lower in male (vs 
female) and patients without steroids at last follow-up. These 
findings once again underline the caution in patients previously 
exposed to anti-TNF and who are under steroids therapy.
 Our study, which is the largest available so far to our 
knowledge, has some limitations: no data of trough levels of 
CT-P13 or antidrug antibodies are available due to economic 
constraints, except in a subgroup of patients published else-
where,53 the mean duration of follow-up is still limited at 1 year, 
and the estimation of remission and response is evaluated by 
different clinicians but corroborated by endoscopic and inflam-
matory biomarkers evaluation. More importantly, no direct 
comparison with infliximab was made. On the other hand, the 
strength of the study is that it reflects the daily practice in the 
large majority of Italian centers prescribing biologic therapy 
in IBD; it also collects a considerable number of patients with 
endoscopic and inflammatory biomarkers, even in pediatric age 
patients who switched from infliximab to CT-P13, and cumula-
tively reports a significant length of time to investigate SAEs. 
Finally, this study is investigator-driven, without any support 
from pharmaceutical companies.
CONCLUSIONS
 In summary, this study demonstrated in the evaluated 
timeframe that the safety profile and effectiveness of CT-P13 
biosimilar is in line with the existing literature of infliximab. No 
alarming signals of immunization have been detected in patients 
switched from infliximab. However, infusion reactions and drug 
discontinuation for infusion reactions were 2- and 3-fold more 
frequent in patients pre-exposed to infliximab, respectively. 
Importantly, this study is reassuring regarding patients after 
the switch; they had a comparable rate of SAEs and signifi-
cantly less loss of response compared with naïve patients and 
previously exposed patients. Not less important is the estimated 
saving of about 4 million Euros for the National Health Service 
in about 1 year of biosimilar utilization.
 The biosimilar infliximab CT-P13 is available almost all 
over the world. Given this growth in the use of biosimilar, it is 
important to fully understand the efficacy and safety in clinical 
use in the long term. More importantly, because multiple biosim-
ilars of the same originator are already available and more are 
to come,54–57 it is possible that patients will undertake multiple 
switches and still not know the consequences of such an environ-
ment for patient safety. Clinical trials, registries, and long-term 
pharmacovigilance studies will provide more evidence to inform 
clinical decision-making and close the gaps in knowledge.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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